Cite
HARVARD Citation
Guttman-Yassky, E. et al. (2021). Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 397 (10290), pp. 2151-2168. [Online].